4DMedical Ltd (ASX: 4DX) shares are leaping higher today.
Shares in the respiratory imaging technology company closed on Friday trading for $3.10. In early afternoon trade on Monday, shares are changing hands for $3.34 apiece, up 7.7%.
For some context, the All Ordinaries Index (ASX: XAO) is up 2.0% at this same time.
Today's outperformance is par for the course for the medical technology stock in recent months.
Indeed, 4DMedical shares are now up an eye-popping 542.3% since this time last year.
That's enough to turn a $10,000 investment into $64,231. In one year.
Of course, those juicy gains have already been delivered.
Which brings us back to our headline question.
Image source: Getty Images
Should you buy 4DMedical shares today?
Ord Minnett's Tony Paterno recently ran his slide rule over the ASX medical tech stock (courtesy of The Bull).
"4DX is a respiratory imaging technology company," Paterno said.
He noted:
4DX enjoyed a positive start to calendar year 2026 after the company announced UC San Diego Health had adopted its CT:VQ product. Also, the company completed a $150 million institutional placement to primarily accelerate the commercialisation of CT:VQ.
CT:VQ, if you're unfamiliar, is the company's CAT scan-based ventilation-perfusion software.
But with 4DMedical shares having rocketed higher over the past six months, Paterno issued a sell recommendation on the stock.
According to Paterno:
The share price has risen from 32 cents on June 2, 2025 to trade at $3.16 on February 5, 2026. In our view, there's a growing disconnect between 4DX's valuation and the uncertainty around near-term CT:VQ revenue generation.
While we remain positive on 4DX's technology, we pull back to a sell recommendation on valuation grounds.
What's been happening with the ASX healthcare share?
The company released its December quarterly results on 30 January, highlighting that the three-month period saw CT:VQ move beyond regulatory approval and into full commercial execution.
4DMedical shares closed down 7.6% on the day, despite the company noting that CT:VQ is being used at a growing number of US health centres. Those include Stanford, the Cleveland Clinic, UC San Diego Health, the University of Miami, and the University of Chicago Medicine.
The company also reported that UChicago Medicine was also going to deploy CT:VQ.
4DMedical CEO and founder Andreas Fouras said:
University of Chicago Medicine is one of the nation's most respected AMCs and a pioneer in medical innovation. Their expansion of our partnership to include CT:VQ represents powerful validation of both the clinical value our technology delivers and the strength of our commercialisation approach.
4DMedical reported a pro forma cash balance of $206 million as at 31 December.
